Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | PPARD | Q03181 | 4/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.54 |
| ▸ | F7 | P08709 | 4/20 | 0.54 |
| ▸ | F3 | P13726 | 4/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703351 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2SLC6A5PPARGALDH1A1PPARD | |
| SCHEMBL3235476 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2SLC6A5PPARGALDH1A1PPARD | |
| SCHEMBL3235483 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2SLC6A5PPARGALDH1A1PPARD | |
| SCHEMBL9656107 | 0.94 | FAAH (0.56) | SMN1; SMN2SLC6A5PPARGPPARDPPARA | |
| SCHEMBL2850175 | 0.94 | FAAH (0.56) | SMN1; SMN2SLC6A5PPARGPPARDPPARA | |
| SCHEMBL7940500 | 0.94 | FAAH (0.56) | SMN1; SMN2SLC6A5PPARGPPARDPPARA | |
| SCHEMBL7940508 | 0.94 | FAAH (0.56) | SMN1; SMN2SLC6A5PPARGPPARDPPARA | |
| SCHEMBL31438435 | 0.85 | ALDH1A1 (0.50) | SMN1; SMN2SLC6A5PPARGALDH1A1PPARD | |
| SCHEMBL2114688 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2SLC6A5FFAR1MAPT | |
| SCHEMBL171001 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2SLC6A5FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20040197399-A1 | N-fatty acid-amino acid conjugates and therapeutic uses | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2004-10-07 | — | — | US | disclosed |
| US-20030022938-A1 | N-fatty acid-amino acid conjugates and therapeutic uses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197399-A1 | N-fatty acid-amino acid conjugates and therapeutic uses | FPR3, FPR1, FPR2 | SMN1; SMN2 1617/4885SLC6A5 1195/4885PPARG 422/4885 |
| US-20030022938-A1 | N-fatty acid-amino acid conjugates and therapeutic uses | FPR3, FPR1, FPR2 | SMN1; SMN2 1617/4885SLC6A5 1195/4885PPARG 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.